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STUDY PROTOCOL Open Access
Treatment with PBI-4050 in patients with
Alström syndrome: study protocol for a
phase 2, single-Centre, single-arm, open-
label trial
Shanat Baig1,2 , Vishy Veeranna1, Shaun Bolton1, Nicola Edwards2,3, Jeremy W. Tomlinson4,
Konstantinos Manolopoulos5, John Moran6, Richard P. Steeds2,3 and Tarekegn Geberhiwot1,5,7*
Abstract
Background: Alström syndrome (ALMS) is a very rare autosomal recessive monogenic disorder caused by a
mutation in the ALMS1 gene and characterised by childhood onset obesity, dyslipidaemia, advanced non-alcoholic
fatty liver disease, diabetes and extreme insulin resistance. There is evidence of multi-organ fibrosis in ALMS and
severity of the disease often leads to organ failure with associated morbidities, resulting in reduced life expectancy.
There are no specific treatments for this disease, and current management consists of only symptomatic therapies.
PBI-4050 is a new molecular entity with demonstrated anti-inflammatory and anti-fibrotic activities in preclinical
models, including animal models of human diseases characterized by progressive fibrosis in the kidney, heart, liver
and lungs. Moreover, completed Phase 2 studies in type 2 diabetes mellitus with metabolic syndrome and
idiopathic pulmonary fibrosis further support the anti-inflammatory and anti-fibrotic activity of PBI-4050. Together,
these data suggest that PBI-4050 has the potential to treat the pathological inflammatory and fibrotic features of
ALMS. The aim of this study is to evaluate the safety and anti-inflammatory & anti-fibrotic activities of PBI-4050 in
subjects with ALMS.
Methods: This is a Phase 2, single-centre, single-arm, open-label trial. A total of 18 patients with ALMS will be
enrolled to receive PBI-4050 at a total daily oral dose of 800 mg for an initial 24 weeks with continuation for an
additional 36 or 48 weeks. Standard assessments of safety include adverse events, clinical laboratory tests, vital
signs, physical examination and electrocardiograms. Efficacy assessments include adipose tissue biopsy,
hyperinsulinaemic-euglycaemic glucose clamp, adipose tissue microdialysis, liver transient elastography, liver
and cardiac magnetic resonance imaging, and laboratory blood tests.
Discussion: This is the first clinical study of PBI-4050 in subjects with ALMS. Given the rarity and complexity of the
disease, a single-centre, single-arm, open-label design has been chosen to maximise subject exposure and increase
the likelihood of achieving our study endpoints. The results will provide valuable safety and preliminary evidence of
the effects of PBI-4050 in ALMS, a rare heterogeneous disease associated with progressive fibrosis and premature
mortality.
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Background
Alström syndrome (ALMS) is a rare autosomal recessive
genetic disorder with an estimated prevalence of less than
one per million [1]. It is characterized by retinal cone-rod
dystrophy, hearing loss, childhood obesity, hyperinsuline-
mia, severe insulin resistance, as well as type 2 diabetes
mellitus (T2DM), hypertriglyceridemia and multiple organ
dysfunctions due to progressive fibrosis. Increasing sys-
temic fibrosis develops as patients age, with clinical mani-
festations in multiple organs. The severity of the disease,
often leading to organ failure with associated morbidities,
results in a reduced life expectancy, rarely exceeding 50
years [1]. There is no specific treatment for this genetic
disease and current management consists of symptomatic
therapies.
ALMS is caused by mutations in ALMS1, a large gene
located on chromosome 2p13 with ubiquitous expres-
sion [2, 3]. The ALMS1 protein localizes to the centro-
somes and basal bodies of ciliated cells and may play a
role in microtubular organization and cilia assembly or
function [3, 4]. In addition, this protein has been impli-
cated in intracellular trafficking, regulation of cilia sig-
nalling pathways, and cellular differentiation among
others [5]. Pathological observations from post-mortem
specimens reveal extensive fibrosis in many organs in-
cluding the kidney, heart, liver, and lung [6]. Further-
more in vitro dermal fibroblast cultures from ALMS
patients display cytoskeleton abnormalities, impaired
migration, increased production of collagens, have aug-
mented cell cycle length, and show enhanced resistance
to apoptosis [7].
PBI-4050 is a potential drug candidate for the treat-
ment of inflammatory and fibrosis-related diseases, in-
cluding idiopathic pulmonary fibrosis, chronic kidney
disease and T2DM with metabolic syndrome. PBI-4050
is a 3-pentylbenzeneacetic acid sodium salt with a mo-
lecular weight of 228.3. It is a new molecular entity with
demonstrated anti-inflammatory and anti-fibrotic activ-
ities in both in vitro and in vivo models. In vitro models
have shown that PBI-4050 regulates macrophages, T
cells, fibrocytes, fibroblasts, myofibroblasts, and epithe-
lial cells and modulates the over-expression of many
pro-inflammatory and pro-fibrotic cytokines and growth
factors in different cell types [8–10]. Moreover, when tested
against normal human dermal fibroblasts stimulated with
transforming growth factor- β, PBI-4050 markedly reduced
the production of pro-fibrotic cytokines, including connect-
ive tissue growth factor (CTGF) and epidermal growth
factor, while restoring the production of anti-fibrotic cyto-
kines such as hepatocyte growth factor [11–14]. PBI-4050
also reduced the production of α-smooth muscle actin, a
marker of myofibroblast activity [15]. Pre-clinical testing
has shown PBI-4050 to be effective in preventing or re-
versing fibrosis in all animal models studied, including
models of fibrosis in the heart, kidney, lung and liver
[12, 13, 16–21]. Furthermore, PBI-4050 has been shown
in a spontaneous model of T2DM (the db/db mouse) to
be effective in preventing the loss of insulin production
that characterizes the natural history in these animals
and leads to death from hyperglycaemia at 24 to 26
weeks of age [22, 23]. Late treatment (from 16 weeks of
age) with PBI-4050 restores insulin production and pre-
serves the islet architecture by reducing macrophage
and T-cell infiltration [9, 16].
Thus, the available pre-clinical data suggest that
PBI-4050 has the potential to treat the pathological in-
flammatory and fibrotic features of ALMS as outlined in
Table 1. Many of these features will be explored in this
study as well. The anti-fibrotic effects of PBI-4050 will
be assessed by measuring blood and urine biomarkers of
Table 1 Major clinical manifestations of Alström syndrome and
corresponding pre-clinical effects of PBI-4050
Clinical features of ALMS Corresponding pre-clinical effects
of PBI-4050
Loss of organ function due to fibrosis involving
Heart ↓ heart fibrosis in suprarenal aortic
banding in rats
Lung ↓ lung fibrosis in bleomycin-induced
lung fibrosis in mice
Liver ↓ liver fibrosis in CCl4-induced liver
fibrosis in rats
Kidneys (renal failure) ↓ kidney fibrosis in various animal
models of kidney fibrosis
Type 2 diabetes mellitus
Early hyperinsulinemia Reduces insulin resistance in db/db
diabetic mice and db/db eNOS−/−
diabetic mice
Severe insulin resistance Normalizes glycaemia in diabetic mice
Late pancreatic failure Maintains (early treatment) or restores
(late treatment) insulin content in
pancreatic islets
eNOS−/− endothelial nitric oxide synthase knockout (mice)
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fibrosis and inflammation and by performing imaging
studies such as transient elastography (TE) or fibroscan
of the liver and magnetic resonance imaging (MRI) of
the heart and liver. The potential effects on insulin sensi-
tivity will be assessed by standard clinical and research
methods, including fasting blood glucose, 4-point glucose
profile, hyperinsulinaemic-euglycaemic clamp and adipose
tissue microdialysis. The data generated will provide valu-
able evidence to support further development of PBI-4050
for the treatment of ALMS.
The actual clinical benefits and risks of PBI-4050 are
currently unknown in subjects with ALMS, as this is
the first study in this subject population. Given the lack
of effective treatment for multi-organ fibrosis, a charac-
teristic of ALMS, the proposed study of PBI-4050 is
justified based on pre-clinical efficacy data in animal
models of fibrosis. Early clinical studies suggest that
PBI-4050 is safe and well tolerated after single-dose
oral administration at doses ranging from 400 to 2400
mg in healthy volunteers (n = 30) and after repeat daily
oral doses of 800 mg in subjects with stable renal im-
pairment (n = 6), T2DM with metabolic syndrome (n =
41), and idiopathic pulmonary fibrosis (n = 26), with
preliminary evidence of clinical activity in the latter two
studies [24, 25]. Across these studies, there have been
no deaths but one subject had a study drug-related
treatment-emergent serious adverse event (SAE) of
pneumonia. Most adverse events (AEs) were mild or
moderate in severity, with headache, insomnia, diar-
rhoea, somnolence, fatigue, and dizziness being the
most frequent study drug-related AEs. In addition,
there were no clinically significant changes in clinical
laboratory, vital signs, or ECG parameters.
Study objectives
The primary objective is to evaluate the safety and toler-
ability of 800 mg PBI-4050 (Investigational Medicinal
Product [IMP]), administered orally once daily.
The secondary objectives are:
 To evaluate the effect of the IMP on metabolic
syndrome parameters
 To evaluate the effect of the IMP on pro-
inflammatory/inflammatory, fibrotic, diabetic, and
obesity biomarkers in blood and urine
 To evaluate the effect of the IMP on antidiabetic
treatment, including oral therapy and insulin
requirements
The exploratory objectives are:
 To examine the effect of the IMP on the histological
appearances of fat biopsies, in particular the degree
of fibrosis and macrophage infiltration;
 To analyse the effect of the IMP on the global
metabolome using systemic blood and adipose
tissue-specific microdialysis samples;
 To analyse the effect of the IMP on the microdialysate
fractions using adipose tissue microdialysis samples;
 To assess the effect of the IMP on liver stiffness
using transient elastography;
 To measure the effect of the IMP on the fat content
and fibrosis burden in the liver using MRI;
 To measure the effect of the IMP on cardiac fibrosis
and function using MRI and on biomarkers,
including N-terminal pro-brain natriuretic peptide
(NT-pro-BNP);
 To evaluate the effect of the IMP on additional pro-
inflammatory/inflammatory, fibrotic, diabetic, and
obesity biomarkers in blood and urine;
 To evaluate the effect of the IMP on glucose, insulin,
and lipid dynamics using the hyperinsulinaemic-
euglycaemic clamp test.
Methods
Study PBI-4050-ATX-9-05 is a Phase 2, single-centre,
single-arm, open-label study of PBI-4050 in subjects
with ALMS. The initial duration of the study is 24
weeks and subjects can elect to enrol into an extension
phase of 36 or 48 weeks and subsequently into the
ALMS rollover study PBI-4050-CT-9-10. The schedule
of study procedures for the enrolment, intervention,
and assessments for participants is outlined in Fig. 1
and Table 2 and presented in detail in Additional file 1
(main study) and Additional file 2 (extension period).
Subjects will be considered enrolled in the main study
at the point when they give written informed consent
and treatment with study drug has commenced. Each sub-
ject will then be assigned a unique identification number
with a country code, site number, and subject number.
Subjects may only be included in the 36- or 48-week ex-
tension period if informed consent is obtained in advance
of any additional study-specific procedures.
Location and setting
Study PBI-4050-ATX-9-05 is sponsored by Prometic
Biosciences and subjects are recruited from the clinical
service at University Hospitals Birmingham NHS Foun-
dation Trust, United Kingdom (UK), which is a nation-
ally commissioned specialist service for ALMS.
Study population and eligibility criteria
A total of 18 subjects will be enrolled. Subjects should
fulfil the following criteria:
 16 years of age or older at screening;
 A diagnosis of ALMS, confirmed by genetic testing
before screening;
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 Subjects on diabetes treatment are receiving the
same antidiabetic agent for a minimum of 1 month
before screening;
 Able and willing to self-monitor blood glucose level
with or without assistance;
 Female subjects of childbearing potential must have
a negative pregnancy test and agree to use adequate
birth control throughout the study and for 30 days
after the last dose of study drug;
 Male subjects are willing to use an acceptable
contraceptive method throughout the study and for
30 days after the last dose of study drug;
 Able to give written informed consent.
Subjects will not enter the study if any of the exclusion
criteria listed in Additional file 3 is fulfilled.
Intervention
PBI-4050 is administered at a total daily oral dose of
800 mg, 1 h before or 2 h after a meal. Subjects are en-
couraged to take PBI-4050 consistently at the same time
every day. Subjects are prohibited from taking the fol-
lowing concomitant medications:
Fig. 1 Flowchart of study design
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 Weight loss medications, including natural products;
 Moderate/potent cytochrome P450 (CYP) 2C9
inhibitors (e.g., amiodarone, fluconazole, miconazole,
and oxandrolone) and moderate/potent CYP2C9
inducers (e.g., carbamazepine and rifampin);
 Strong CYP3A inhibitors (e.g., ketoconazole,
itraconazole, clarithromycin) and strong CYP3A
inducers (e.g., rifampin, phenytoin, carbamazepine,
and St. John’s wort).
Study procedure
Assessment of safety and tolerability
AEs will be assessed by the investigator starting from
screening through 30 days after the last dose of study
drug. AEs occurring at the time of the first dose of study
drug are referred to as treatment-emergent AEs.
A complete physical examination along with ECGs and
vital signs will be performed at each visit. Fasting blood
and urine samples will also be collected at each visit for
monitoring safety, including haematology, biochemistry,
and urinalysis. Clinically significant changes in any of
these parameters will be recorded as AEs.
Haematology includes complete blood cell count
(CBC), which includes red blood cell count (RBC),
haematocrit, and haemoglobin; white blood cell (WBC)
count with 5-part differentials (absolute values); and
platelet count. Biochemistry includes electrolytes (cal-
cium, sodium, potassium, phosphate, and magnesium),
liver function (aspartate aminotransferase [AST], alanine
aminotransferase [ALT], gamma-glutamyl transferase
[GGT], and total bilirubin), other enzymes and substrates
(alkaline phosphatase [ALP]), urea, uric acid, creatinine,
albumin, and lactate dehydrogenase, and lipid profile
(total cholesterol, HDL-C, low-density lipoprotein choles-
terol [LDL-C], triglycerides, total plasma protein).
Urinalysis will include the following macroscopic exami-
nations: pH, specific gravity, protein, glucose, ketones,
blood, nitrite, and leukocytes. If the macroscopic shows
any abnormal findings, microscopic examination will be
performed. Urine pregnancy test will be performed for
women with childbearing potential.
Study subjects will be instructed to measure fasting
blood glucose each morning and 4-point blood glucose
profiles weekly, with the results recorded in a diary.
Study personnel will contact the subjects by phone
weekly to review the blood glucose results. Subject diar-
ies will be reviewed at each study visit. Hypoglycaemic
episodes will be classified as AEs of special interest and
defined as follows:
 Suspected symptomatic hypoglycaemia: Symptoms
of hypoglycaemia (shaking, dizziness, blurred vision,
palpitations, sweating, etc.) with no confirmatory
blood glucose level, or blood glucose 3.5–3.9 mmol/
L with or without symptoms.
 Confirmed hypoglycaemia: Blood glucose < 3.5
mmol/L with or without symptoms (shaking,
dizziness, blurred vision, palpitations, sweating, etc.).
Table 2 Study visits
Visit Screen Wk 1 Wk 4 Wk 8 Wk 12 Wk 16 Wk 20 Wk 24 EP 12 EP 24 EP 36 EP 48 EoS
Informed consent X X
Demography and History X
Physical examination X X X X X X X X X
Vital signs X X X X X X X X X X X X X
Weight & waist X X X X X X X X X X X X X
Haematology/Biochemistry X X X X X X X X X X X X X
Urinalysis X X X X X X X X X X X X X
12-lead ECG X X X X X X X X X
IMP accountability X X X X X X X X X X X
Fasting glucose profile X X X X X X X X X X X X
Adverse events X X X X X X X X X X X X
Concomitant medications X X X X X X X X X X X X
FibroScan X X X X X X X
Liver/Cardiac MRI X X X
Insulin clamp/Microdialysis X X
Adipose tissue biopsy X X
Metabolic syndrome parameter X X X X X X X
Biomarkers X X X X X X X X X X X
Screen Screening visit, Wk weeks, EP Extension phase visits
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 Severe hypoglycaemia events: Blood glucose < 3.0
mmol/L and/or loss of consciousness.
Details of safety endpoints will be captured on the
study electronic case report form.
Assessment of metabolic syndrome parameters and
biomarkers
Blood samples will be drawn to measure the following
metabolic syndrome parameters: Fasting plasma glucose
(FPG), Glycated haemoglobin (HbA1c), fasting insulin.
HbA1c will be measured at each visit and FPG and fast-
ing insulin will be measured every 12 weeks, as shown in
the Schedule of Study Procedures. Homeostasis Model
Assessment (HOMA2) for steady state beta cell function
(HOMA2-B) and for insulin resistance (HOMA2-IR) will
be calculated.
Blood and urine samples will also be collected to meas-
ure pro-inflammatory/inflammatory, diabetic, obesity, and
fibrotic markers. These include Interferon gamma (IFNγ),
cystatin C, interleukin (IL)-6, IL-8, monocyte chemo-
attractant protein-1 (MCP-1), tumour necrosis factor
alpha (TNFα), IL-10, vascular endothelial growth factor
(VEGF), adiponectin, and glucagon in blood and Albu-
min/creatinine ratio (ACR) and MCP-1 in urine.
Additional pro-inflammatory/inflammatory, fibrosis,
diabetic and obesity biomarkers in blood (plasma) and
urine will be measured for exploratory analysis. The
biomarkers to be analysed will include but are not limited
to: free fatty acid (FFA), cholecystokinin (CCK), leptin,
adipsin, ghrelin, resistin, visfatin, c-peptide, glucagon-like
peptide 1 (GLP-1), plasminogen activator inhibitor 1
(PAI-1), gastric inhibitory peptide (GIP), alpha-1 antitryp-
sin (AAT), connective tissue growth factor (CTGF), inter-
cellular adhesion molecule (ICAM-1), fibrinogen, and
nitric oxide (NO) (all in plasma).
The above biomarkers will be analysed by the study
site’s local research laboratory and partners as well as
ProMetic BioSciences Inc.
Assessment of liver fibrosis
Transient Elastography (TE) is one of several methods, in-
cluding liver MRI and the enhanced liver fibrosis (ELF)
test, to measure the presence of liver fibrosis and response
to PBI-4050. TE is a non-invasive technique to assess liver
stiffness by measuring the velocity of sheer waves through
the liver [26–28]. TE is performed using a Fibroscan
(Echosense, France) with an M-probe (3.5 Hz frequency)
or XL-probe (2.5 Hz frequency). All assessments are per-
formed in the dorsal decubitus position with the ultra-
sound probe tip overlying the right lobe of liver [29].
MRI of the liver will be used to quantify liver fibrosis
and response to PBI-4050. Using a 1.5 T (Siemens Avanto)
scanner, the sequences acquired include 1) a central slice
Shortened Modified Look-Locker Inversion recovery T1
sequence that times the longitudinal relaxation of each
imaged voxel; 2) a multi-slice Spin Echo Imaging Inver-
sion Recovery T1 mapping sequence; 3) a central slice
high resolution T2 sequence that times the transverse re-
laxation of each imaged voxel; and 4) a central slice Dixon
sequence that is used to separate water and fat.
An Enhanced Liver Fibrosis (ELF) test will be per-
formed. The ELF test consists of three serum biomarkers
and correlates with levels of liver fibrosis [30].
Assessment of cardiac fibrosis
Cardiac MRI will be used to quantify cardiac fibrosis
and response to PBI-4050. Using a 1.5 T (Siemens
Avanto) scanner left and right ventricular volumes,
mass and function will be acquired using standard pro-
tocols. T1 mapping will be performed before and after
gadolinium contrast using a Modified Look Locker
Inversion recovery sequence employing a 5 s(3 s)3 s
sampling protocol (average breath hold 10–15 s) to
quantify diffuse myocardial fibrosis. Late gadolinium
enhancement imaging will be performed 7–10 min after
0.15 mmol/Kg of gadolinium contrast bolus (Gadovist
Bayer Health Care) to quantify extent of coarse replace-
ment fibrosis [31].
Assessment of adipose tissue
Adipose tissue samples will be used to quantify the effects
of PBI-4050 on fibrosis in adipocytes. Subcutaneous adi-
pose tissue from ALMS subjects is to be characterised
using histo-morphometry and immunohistochemistry
staining. The biopsies are collected from the abdomen on
the lateral side of the umbilicus on the abdominal wall.
After administration of local anaesthetic (1% lignocaine), a
1-cm subcutaneous incision is made with a scalpel and
the removed sample of adipose tissue is immediately pre-
served in 2 parts in formalin and RNAlater® Stabilization
Solution (Thermofisher scientific). The samples stored
in formalin are then embedded in paraffin to make
formalin-fixed paraffin-embedded (FFPE) blocks. The
FFPE blocks are cut and stained with haematoxylin and
eosin and picrosirius-red staining for quantification of
adipose tissue fibrosis. Adipocyte size is measured by
means of light microscopy. Immunohistochemistry with
macrophage, T-cell and collagen markers will be per-
formed to quantify inflammatory activity and collagen
deposition. Global gene expression in adipocytes will be
measured. Adipose tissue stored in RNAlater is pre-
pared using RNeasy Lipid Tissue (QIAGEN) and next
generation gene sequencing performed to access ex-
pression of pro-fibrotic genes.
Adipose tissue microdialysis is used to sample interstitial
fluid intermediary metabolites in the form of glycerol,
glucose, pyruvate and lactate, which act as a marker of
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adipose tissue lipolysis. A microdialysis catheter (CMA
microdialysis [CMA 106/107], Sweden) is inserted
approximately 10 cm lateral to and at the level of the
umbilicus via a subcutaneous incision after local anaes-
thetic (1% lignocaine). Samples are collected every 30
min into micro-vials (0.3 μL/min) until the end of the
hyperinsulinaemic-euglycaemic glucose clamp.
Assessment of insulin secretion and resistance
The hyperinsulinaemic-euglycaemic glucose clamp is
considered the gold standard for quantifying insulin se-
cretion and resistance and will be used to monitor the
effects of PBI-4050 on insulin resistance in ALMS [32].
In effect, blood glucose lowering effects of insulin are
antagonised by glucose infused at a variable rate to keep
blood glucose clamped at a specific fasting level [33].
Subjects are required to fast overnight before starting
the hyperinsulinaemic-euglycaemic clamp at 0900 am
the following morning. Fasting glucose is recorded and
subjects are then clamped at that level. Subjects are
given a bolus (2 mg/kg) of D-Glucose (U-13C6) (Cam-
bridge Isotope Laboratories, UK) before a continuous in-
fusion of D-glucose (20 μg/kg/min) for the next 4 h. An
infusion of potassium palmitate 2, 2 D2 (Cambridge Iso-
tope Laboratories, UK) in 5% albumin (0.03 μmol/kg/
min) is given at the same time and continues for next 4
h until the end of procedure. During the first 2 h (basal
phase), blood glucose is checked every 15min and add-
itional bloods are taken at time points 0, 90, 105, and
120 min for measurement of insulin, free fatty acid and
stable isotopes for the assessment of whole body basal
glucose turnover. Samples taken at time points 0, 90,
105, 120, 210, 225 & 240 will also be analysed with an-
other reference laboratory method and clamp quality for
these paired samples reported according to Benesch et
al., 2015.
Insulin (Actrapid; Novo Nordisk, Copenhagen, Denmark)
infusion is then started at 120min at a rate of 40mU/m2/
min. Four minutes later, a 20% dextrose solution with
[13C]-glucose (enriched to 4%) is commenced at time point
124min. During the insulin-stimulated state period, blood
sugars are checked every 5min to allow for dextrose infu-
sion rate adjustments to maintain fasting glycaemic levels.
At time points 210, 225 and 240min, steady state blood
samples are collected. The rates of endogenous glucose
production, glucose disposal and lipolysis (Rd - rate of dis-
posal of palmitate) are calculated.
Discontinuation or withdrawal of study subjects
PBI-4050 will be permanently discontinued for the fol-
lowing reasons:
 Subject’s withdrawal of consent;
 An AE, which in the opinion of the investigator
warrants discontinuation of treatment;
 Pregnancy;
 Death;
 Substantial protocol deviation;
 Investigator’s decision;
 Sponsor’s decision;
 Subject starting a prohibited therapy (see Section 5.6);
 aspartate transaminase or alanine transaminase rises
to > 5 × upper limit of normal;
 A drop in heart rate from baseline by 15 beats per
minute that is associated with clinically relevant
cardiovascular symptoms as determined by the
investigator;
 A drop in systolic blood pressure by 20mmHg or
diastolic blood pressure by 15mmHg from baseline
that is associated with clinically relevant cardiovascular
symptoms as determined by the investigator.
Subjects who discontinue study treatment but have not
withdrawn consent will be asked to attend the appropriate
End-of-Treatment and End-of-Study visits, depending
upon whether they withdraw before or after Week 24.
Subjects who withdraw consent will not have further
study-related information collected for the clinical trial
database, with the exception of follow-up on on-going
AEs or any new AEs within the safety follow-up period.
Subjects who withdraw due to AEs will be followed until
the event has resolved or stabilized.
In the case of any substantial deviation from the
protocol, the investigator and sponsor will decide on the
further participation of the subject in this study, having
discussed all relevant aspects. The sponsor may discon-
tinue the study in its entirety before its completion for
reasonable cause, provided that written notice to the in-
vestigator, regulatory authorities and independent ethics
committee (EC) is submitted in reasonable time in ad-
vance of the intended termination.
If subjects decide to enter the ALMS rollover study
(Study PBI-4050-CT-9-10) after completing the 36- or
48-week extension period, then they will sign an in-
formed consent for that study and stop participation in
the current study.
Pharmacovigilance and data monitoring
All SAEs will be reported to pharmacovigilance/safety
personnel within 24 h after the investigator becomes
aware of the event. All relevant information about any
suspected unexpected serious adverse reaction (SUSAR)
occurring during the course of a clinical trial and if fatal
or life-threatening will be reported as soon as possible and
in any event not later than 7 days to the competent au-
thority. All SUSARs occurring in the interventional study
will be entered into a European database established in
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accordance Directive 2001/20/EC and reported to the
relevant ECs. A Data Safety Monitoring Board will review
individual subject safety data in an on-going fashion. An
unaffiliated clinical research associate will monitor the
data collected throughout the study, thus providing qual-
ity control (QC) of the study and QC of the database and
data management.
Sample size and statistical analysis
This study is purely exploratory and aims to evaluate
safety and tolerability of PBI-4050 and examine its effects
on biomarkers. The study will collect data to derive
descriptive statistics on secondary endpoints for future
studies and no statistical hypothesis will be tested. A mini-
mum of 8 subjects is deemed necessary in this part of the
study. The data will be summarized using mean, standard
deviation, median, and range. Demographic (sex, age, race,
ethnicity, waist circumference, height, weight, and BMI)
and baseline characteristics will be presented descriptively
at baseline. Categorical variables will be reported as num-
bers and percentages. Paired t-test or where appropriate
the non-parametric equivalent (Wilcoxon signed-rank
test) will be used to compare variables before and after
intervention. The Shapiro-Wilk test will be used to test
the normality of the distribution. In the event that the
normality assumption fails at the 0.10 alpha level of sig-
nificance, the Wilcoxon Signed-Rank test will be used in-
stead. Absolute values and changes from baseline in safety
laboratory tests will be summarized by visit over time and
presented in shift tables. To evaluate the shift over time, a
mixed model comparing the slope before baseline (histor-
ical data) to the slope after baseline (on-treatment data)
will be used. For comparing results of repeated samples,
for example adipose tissue microdialysis where there are
multiple time points during the same test, repeated mea-
sures analysis of variance will be used. All analysis will be
conducted using SPSS statistical software. The significance
level for this study is set at p < 0.05. All statistical analyses
will be made using observed data. No imputation will be
made.
Discussion
ALMS is a rare genetic disease characterised by multi-
organ dysfunction and progressive fibrosis, resulting in
reduced life expectancy [1]. Given its rarity and com-
plexity, clinical trials in this disease are challenging.
The national centre for ALMS in Birmingham UK was
selected as the centre able to deliver this study in 18
subjects. A single-arm, open-label design was selected
to maximise subject exposure and increase the likeli-
hood of achieving the chosen study endpoints.
Study PBI-4050-ATX-9-05 will initially evaluate the
safety and tolerability of PBI-4050 over a 24-week
period, during which therapeutic efficacy in terms of
modification of the metabolic syndrome, liver and car-
diac fibrosis and pro-inflammatory and pro-fibrotic state
will be assessed, followed by an exploratory phase in
those subjects who are tolerating therapy. Because of the
complexity of the ALMS phenotype, a variety of investi-
gations are incorporated into the study. This study is not
intended as a full assessment of the safety and efficacy of
PBI-4050. Rather, this study will provide valuable safety
and biomarker evidence to support further development
of PBI-4050 for the treatment of ALMS, a disease with
severe morbidity and early mortality in which PBI-4050
has the potential to improve these outcomes.
Trial status
Recruitment to Study PBI-4050-ATX-9-05 began in
February 2016. The study has recruited 12 subjects in
the main study and 9 subjects in the extension phase.
The study is currently recruiting in the UK and sched-
uled to end in 2018.
Additional files
Additional file 1: Schedule of Study Procedures (Main Study). Study
Visits Initial 24 Weeks. Study Visits during the Initial 24 Weeks of
Treatment. The schedule of study procedures for the enrolment,
intervention, and assessments for participants is presented in detail in
Additional file 1 (main study) and Additional file 2 (extension period).
(PDF 218 kb)
Additional file 2: Schedule of Study Procedures (Extension Period).
Study Visits during Extension Period. Study Visits During the 36- or 48-
Week Extension Period. The schedule of study procedures for the enrol-
ment, intervention, and assessments for participants is presented in detail
in Additional file 1 (main study) and Additional file 2 (extension period).
(PDF 207 kb)
Additional file 3: Exclusion criteria. This file list the exclusion criteria for
the study. Subjects will not enter the study if any of the exclusion criteria
listed in Additional file 3 is fulfilled. (PDF 281 kb)
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